Skip to main content
Clinical Trials/NCT03520218
NCT03520218
Completed
Not Applicable

A Pilot Study to Evaluate Low-Dose Positron Emission Mammography Imaging in Visualization and Characterization of Suspicious Breast Abnormalities

University Health Network, Toronto1 site in 1 country25 target enrollmentDecember 17, 2019
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
University Health Network, Toronto
Enrollment
25
Locations
1
Primary Endpoint
Evaluating Performance of the R-PEM system as the Dose Decays
Status
Completed
Last Updated
last year

Overview

Brief Summary

The goal of this pilot project is to test the new Radialis Positron Emission Mammography (R-PEM) system in breast cancer patients that has a higher sensitivity with lower radiation doses than conventional PET/CT.

The plan for the pilot study is to image patients who are already scheduled for diagnostic imaging for breast cancer after a positive core biopsy. Participants will be injected with 5mCi (millicurie) of F18-Fluorodeoxyglucose (FDG) and patient will wait for a couple of hours for uptake of FDG. After this time, the first R-PEM scan will occur. Additional optional R-PEM scans can be performed 4 hours after injection and 7 hours after injection with reductions in radiation emission.

Additionally, R-PEM images will be compared to standard-of-care breast Magnetic Resonance Imaging (MRI) and digital breast tomosynthesis (DBT) to study extension of disease and screening of contralateral breast.

Registry
clinicaltrials.gov
Start Date
December 17, 2019
End Date
November 3, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject is female of any race and ethnicity
  • Subject is at least 26 years old
  • Following routine mammography imaging, subject is categorized as BI-RADS score 4C or 5 because of calcifications, masses, asymmetries or/and architectural distortion will undergo additional tests including biopsy within 30 days of routine imaging
  • Subject is female with a recent breast biopsy confirming breast cancer

Exclusion Criteria

  • Subject unable or unwilling to undergo informed consent
  • Subjects who are unable or unwilling to tolerate any of the imaging tests because of claustrophobia, compression, etc.
  • Subjects who are pregnant or who think they may be pregnant
  • Subjects who are breast-feeding
  • Subjects weight exceed table limits of MRI and PET-CT (300-450 lb or 135-205 kg)
  • Subjects with history of allergic reaction to gadolinium or previous history of life-threatening anaphylactic reaction to any contrast.
  • Claustrophobic subjects

Outcomes

Primary Outcomes

Evaluating Performance of the R-PEM system as the Dose Decays

Time Frame: 2 years

The diagnostic performance of R-PEM including sensitivity, specificity, positive and negative predictive values compared to magnetic resonance imaging, digital breast tomosynthesis mammography, and digital mammography in characterization of suspicious breast abnormalities will also be evaluated in our study when those images are available through standard patient care.

Study Sites (1)

Loading locations...

Similar Trials